Clinical

Dataset Information

0

A clinical trial of Vedolizumab vs. placebo (dummy drug) for the prevention of intestinal Acute Graft Versus Host Disease (aGvHD), in patients undergoing allo-HSCT for a hematologic malignancy, (cancers that affect the blood and/or lymphatic system).


ABSTRACT: Main Objective: To evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in subjects who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. Primary end point(s): The primary endpoint is intestinal aGvHD-free survival by Day +180 after allo HSCT. Intestinal aGvHD is defined as Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria.

DISEASE(S): Acute Graft Versus Host Disease In Intestine,Intestinal Acute Graft-versus-host Disease (agvhd)

PROVIDER: 2554383 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-03-06 | GSE230788 | GEO
2017-05-12 | GSE81397 | GEO
| S-EPMC4988402 | biostudies-literature
| S-EPMC5479876 | biostudies-other
2021-09-28 | GSE182678 | GEO
2021-12-21 | GSE124426 | GEO
2024-09-11 | GSE243364 | GEO
2024-09-11 | GSE223814 | GEO
2024-09-11 | GSE223368 | GEO
2018-11-05 | ST001089 | MetabolomicsWorkbench